Aurora Board Rejects Curaleaf's US$5.00 Hostile Bid; Discloses Bargain-Purchase Accounting and US$24M Officer Payouts
ACB sits 65% above its 52-week low of $2.56 on light trading volume (0.1× avg).
Summary
Aurora's board again urges shareholders to reject Curaleaf's revised US$5.00 hostile bid, citing an updated fairness opinion and newly disclosed accounting that values Aurora's business at barely more than its net assets. The special committee is running a strategic alternatives process with multiple interested parties ahead of the December 4, 2026 bid expiry.
Key Events · M&A and Partnerships · ACB
-
Board Rejects Revised US$5.00 Bid
Aurora's board unanimously recommends shareholders reject Curaleaf's revised hostile bid of US$1.00 cash plus 0.4013 Curaleaf shares per Aurora share (implied US$5.00, capped at US$6.00), and withdraw any tendered shares.
-
Updated Fairness Opinion Calls Bid Inadequate
Fort Capital's October 14, 2026 opinion states the revised consideration remains inadequate from a financial point of view; the prior opinion was dated September 1, 2026.
-
Curaleaf Accounting Shows Minimal Goodwill
Curaleaf's preliminary purchase price allocation shows US$328.7M consideration (US$4.92/share) against US$313.2M identifiable net assets (US$4.68/share), leaving goodwill of only US$15.6M, or 4.7% of the price, with a bargain purchase gain under certain scenarios.
-
Bid Cash Funded From Aurora's Own Balance Sheet
The ~US$67M aggregate cash component is less than Aurora's US$108M of cash, equivalents, restricted cash and short-term investments as at June 30, 2026, meaning shareholders would effectively fund the cash portion themselves.
Analysis · ACB · Life Sciences
Aurora's board formally recommends shareholders reject Curaleaf's revised US$5.00-per-share hostile bid, backed by an updated Fort Capital opinion that the consideration remains inadequate. The new substance is in the disclosure Curaleaf was forced to make: its own purchase price allocation values Aurora's identifiable net assets at US$313.2M against US$328.7M of consideration, leaving goodwill of just US$15.6M (4.7% of the price) and producing a bargain purchase gain under some scenarios — accounting that implies Curaleaf is paying little for Aurora beyond its balance sheet. Aurora also shows the ~US$67M cash component of the bid could be funded entirely from Aurora's own US$108M of cash, and that its stock is more liquid than Curaleaf's (C$11.8M vs C$8.8M average daily value traded). The bid is open until December 4, 2026, and Aurora's special committee says it is in active talks with multiple parties under confidentiality and standstill agreements, so a superior proposal could still emerge. Shareholders who tender now give up that optionality for a bid the board says undervalues the company.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.9M. The 52-week trading range was $2.56 to $6.36. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.